FDA Drug · D-1302-2020

oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV Use, Rx only, QuVa Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 888-339-0874, NDC 70092-1068-07

Class II · Terminated

Subpotent drug - Product did not contain drug.

Affected lots / codes — check yours against thisLot#: 30010515

Recalling firm: QuVa Pharma, Inc., Sugar Land, TX
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 648 bags
Distribution: USA Nationwide
Recall initiated: May 28, 2020
Classified: June 11, 2020
Terminated: January 19, 2022
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1302-2020%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →